Concert Pharmaceuticals Inc. (CNCE)

10.76
NASDAQ : Health Technology
Prev Close 11.02
Day Low/High 10.69 / 11.16
52 Wk Low/High 9.21 / 20.21
Avg Volume 320.60K
Exchange NASDAQ
Shares Outstanding 23.80M
Market Cap 262.23M
EPS -2.40
P/E Ratio N/A
Div & Yield N.A. (N.A)
Concert Pharmaceuticals Announces Completion Of Enrollment In First Cohort Of CTP-543 Phase 2a Trial

Concert Pharmaceuticals Announces Completion Of Enrollment In First Cohort Of CTP-543 Phase 2a Trial

Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it has completed enrollment of the first cohort of its Phase 2a trial evaluating CTP-543.

Concert Pharmaceuticals To Report Third Quarter 2017 Financial Results On November 9, 2017, And Participate At Upcoming Investor Conferences

Concert Pharmaceuticals To Report Third Quarter 2017 Financial Results On November 9, 2017, And Participate At Upcoming Investor Conferences

Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it will report its third quarter 2017 financial results on Thursday, November 9, 2017, before the U.

Concert Pharmaceuticals Announces PTAB Denies Incyte Petition Challenging CTP-543 Patent

Concert Pharmaceuticals Announces PTAB Denies Incyte Petition Challenging CTP-543 Patent

Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that the Patent Trials and Appeal Board (PTAB) of the U.

Commit To Purchase Concert Pharmaceuticals At $12.50, Earn 19.5% Annualized Using Options

Commit To Purchase Concert Pharmaceuticals At $12.50, Earn 19.5% Annualized Using Options

Investors eyeing a purchase of Concert Pharmaceuticals Inc shares, but cautious about paying the going market price of $14.65/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the January 2018 put at the $12.50 strike, which has a bid at the time of this writing of 85 cents.

Concert Pharmaceuticals Announces Webcast At Wells Fargo Healthcare Conference

Concert Pharmaceuticals Announces Webcast At Wells Fargo Healthcare Conference

Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it will present a corporate overview at the Wells Fargo 2017 Healthcare Conference on Thursday, September 7, 2017, at 11:10 a.

Concert Pharmaceuticals Reports Second Quarter 2017 Financial Results And Provides Company Update

Concert Pharmaceuticals Reports Second Quarter 2017 Financial Results And Provides Company Update

Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today reported financial results for the second quarter of 2017.

Concert Pharmaceuticals To Report Second Quarter 2017 Financial Results On August 8, 2017

Concert Pharmaceuticals To Report Second Quarter 2017 Financial Results On August 8, 2017

Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it will report its second quarter 2017 financial results on Tuesday, August 8, 2017, before the U.

Vertex And Concert Pharmaceuticals Complete Asset Purchase Agreement For CTP-656

Vertex And Concert Pharmaceuticals Complete Asset Purchase Agreement For CTP-656

Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) and Concert Pharmaceuticals, Inc.

Concert Pharmaceuticals Announces Termination Of The HSR Act Waiting Period For CTP-656 Asset Purchase Agreement With Vertex

Concert Pharmaceuticals Announces Termination Of The HSR Act Waiting Period For CTP-656 Asset Purchase Agreement With Vertex

Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that the U.

FDA Lifts Clinical Hold On Concert Pharmaceuticals Clinical Trial With CTP-543

FDA Lifts Clinical Hold On Concert Pharmaceuticals Clinical Trial With CTP-543

Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) today announced that the U.

Concert Pharmaceuticals Announces $30 Million Venture Debt Financing From Hercules Capital

Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it has entered into a $30.

Commit To Buy Concert Pharmaceuticals At $10, Earn 17% Annualized Using Options

Investors eyeing a purchase of Concert Pharmaceuticals Inc shares, but tentative about paying the going market price of $13.27/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the January 2018 put at the $10 strike, which has a bid at the time of this writing of $1.05.

Oversold Conditions For Concert Pharmaceuticals (CNCE)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Concert Pharmaceuticals To Present At Upcoming Investor Conferences

Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it will present a corporate overview at the Jefferies 2017 Global Healthcare Conference on June 6, 2017, at 10:30 a.

Concert Pharmaceuticals Announces Departure Of Chief Financial Officer, Ryan Daws

Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that Ryan Daws, Chief Financial Officer, will be leaving the company in early June 2017 to return to investment banking.

Concert Pharmaceuticals Announces Shareholder Approval Of CTP-656 Asset Purchase Agreement With Vertex Pharmaceuticals

Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that in connection with its annual shareholder meeting, Concert shareholders voted to approve the asset purchase agreement under which Vertex...

Vertex Undergoes FTC Scrubbing for Deal on CF Treatment

Vertex Undergoes FTC Scrubbing for Deal on CF Treatment

The key issue for the FTC is whether the deal kills competition between Concert's treatment and Vertex's Kalydeco.

Concert Pharmaceuticals Receives Second Request From FTC Under HSR Act

Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it has received a request for additional information ("Second Request") from the United States Federal Trade Commission (FTC) in connection with the...

Hold on Concert's Hair Loss Trials Pushes Shares Down 10%

Hold on Concert's Hair Loss Trials Pushes Shares Down 10%

Concert must submit toxicology data to the FDA before proceeding with Phase 2 trials.

Concert Pharmaceuticals Announces Clinical Hold On CTP-543 Phase 2a Trial

Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it has received notice from the U.

Oversold Conditions For Concert Pharmaceuticals (CNCE)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Concert Pharmaceuticals Reports First Quarter 2017 Financial Results

Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today reported financial results for the first quarter of 2017.

Concert Pharmaceuticals Initiates CTP-543 Phase 2 Trial In Alopecia Areata

Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced the initiation of a Phase 2a clinical trial evaluating CTP-543 for the treatment of moderate-to-severe alopecia areata, an autoimmune disorder in which the...

Concert Pharmaceuticals To Report First Quarter 2017 Financial Results On May 2, 2017, And Present At Upcoming Investor Conferences

Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it will report its first quarter 2017 financial results on Tuesday, May 2, 2017, before the U.

Why Concert Pharmaceuticals Is Music to Investors' Ears

Why Concert Pharmaceuticals Is Music to Investors' Ears

This little biotech packed a big wallop on Monday as its stock nearly doubled. Here's why.

Commit To Purchase Concert Pharmaceuticals At $15, Earn 26.5% Annualized Using Options

Investors eyeing a purchase of Concert Pharmaceuticals Inc shares, but tentative about paying the going market price of $16.71/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the October put at the $15 strike, which has a bid at the time of this writing of $2.45.

What You Must Know About Cystic Fibrosis Drug CTP-656

What You Must Know About Cystic Fibrosis Drug CTP-656

Acquiring CTP-656 from Concert Pharmaceuticals will only cost Vertex around $250 million.

Concert Pharmaceuticals Reports Year Ended 2016 Financial Results

Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) today reported financial results for the year ended December 31, 2016, as well as provided an update on its product pipeline and corporate activities.

Vertex Pharma Acquires Long-Acting Version of Cystic Fibrosis Drug From Concert Pharma

Vertex Pharma Acquires Long-Acting Version of Cystic Fibrosis Drug From Concert Pharma

The convenience of a once-daily version of Kalydeco is important to Vertex because it has the potential to simplify dosing of combination regimens the company has in development.

Vertex To Acquire CTP-656 From Concert Pharmaceuticals For The Treatment Of Cystic Fibrosis

Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it has signed a definitive asset purchase agreement with Vertex Pharmaceuticals, Inc.

TheStreet Quant Rating: D (Sell)